Last reviewed · How we verify
AL-794 suspension
At a glance
| Generic name | AL-794 suspension |
|---|---|
| Sponsor | Alios Biopharma Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study (PHASE1)
- A Study to Assess the PK of AL-794 Formulations in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AL-794 suspension CI brief — competitive landscape report
- AL-794 suspension updates RSS · CI watch RSS
- Alios Biopharma Inc. portfolio CI